Cargando…
Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study
A recent experimental study suggested that proton pump inhibitors (PPI), widely used to prevent gastroduodenal complications of dual antiplatelet therapy, may increase the accumulation of the endogenous nitric oxide synthesis antagonist asymmetric dimethylarginine (ADMA), an adverse outcome predicto...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848910/ https://www.ncbi.nlm.nih.gov/pubmed/27092494 http://dx.doi.org/10.3390/ijms17040454 |
_version_ | 1782429445856952320 |
---|---|
author | Kruszelnicka, Olga Świerszcz, Jolanta Bednarek, Jacek Chyrchel, Bernadeta Surdacki, Andrzej Nessler, Jadwiga |
author_facet | Kruszelnicka, Olga Świerszcz, Jolanta Bednarek, Jacek Chyrchel, Bernadeta Surdacki, Andrzej Nessler, Jadwiga |
author_sort | Kruszelnicka, Olga |
collection | PubMed |
description | A recent experimental study suggested that proton pump inhibitors (PPI), widely used to prevent gastroduodenal complications of dual antiplatelet therapy, may increase the accumulation of the endogenous nitric oxide synthesis antagonist asymmetric dimethylarginine (ADMA), an adverse outcome predictor. Our aim was to assess the effect of PPI usage on circulating ADMA in coronary artery disease (CAD). Plasma ADMA levels were compared according to PPI use for ≥1 month prior to admission in 128 previously described non-diabetic men with stable CAD who were free of heart failure or other coexistent diseases. Patients on PPI tended to be older and with insignificantly lower estimated glomerular filtration rate (GFR). PPI use was not associated with any effect on plasma ADMA (0.51 ± 0.11 (SD) vs. 0.50 ± 0.10 µmol/L for those with PPI (n = 53) and without PPI (n = 75), respectively; p = 0.7). Additionally, plasma ADMA did not differ between PPI users and non-users stratified by a history of current smoking, CAD severity or extent. The adjustment for patients’ age and GFR did not substantially change the results. Thus, PPI usage does not appear to affect circulating ADMA in non-diabetic men with stable CAD. Whether novel mechanisms of adverse PPI effects on the vasculature can be translated into clinical conditions, requires further studies. |
format | Online Article Text |
id | pubmed-4848910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-48489102016-05-04 Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study Kruszelnicka, Olga Świerszcz, Jolanta Bednarek, Jacek Chyrchel, Bernadeta Surdacki, Andrzej Nessler, Jadwiga Int J Mol Sci Article A recent experimental study suggested that proton pump inhibitors (PPI), widely used to prevent gastroduodenal complications of dual antiplatelet therapy, may increase the accumulation of the endogenous nitric oxide synthesis antagonist asymmetric dimethylarginine (ADMA), an adverse outcome predictor. Our aim was to assess the effect of PPI usage on circulating ADMA in coronary artery disease (CAD). Plasma ADMA levels were compared according to PPI use for ≥1 month prior to admission in 128 previously described non-diabetic men with stable CAD who were free of heart failure or other coexistent diseases. Patients on PPI tended to be older and with insignificantly lower estimated glomerular filtration rate (GFR). PPI use was not associated with any effect on plasma ADMA (0.51 ± 0.11 (SD) vs. 0.50 ± 0.10 µmol/L for those with PPI (n = 53) and without PPI (n = 75), respectively; p = 0.7). Additionally, plasma ADMA did not differ between PPI users and non-users stratified by a history of current smoking, CAD severity or extent. The adjustment for patients’ age and GFR did not substantially change the results. Thus, PPI usage does not appear to affect circulating ADMA in non-diabetic men with stable CAD. Whether novel mechanisms of adverse PPI effects on the vasculature can be translated into clinical conditions, requires further studies. MDPI 2016-04-15 /pmc/articles/PMC4848910/ /pubmed/27092494 http://dx.doi.org/10.3390/ijms17040454 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kruszelnicka, Olga Świerszcz, Jolanta Bednarek, Jacek Chyrchel, Bernadeta Surdacki, Andrzej Nessler, Jadwiga Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study |
title | Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study |
title_full | Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study |
title_fullStr | Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study |
title_full_unstemmed | Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study |
title_short | Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study |
title_sort | asymmetric dimethylarginine versus proton pump inhibitors usage in patients with stable coronary artery disease: a cross-sectional study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848910/ https://www.ncbi.nlm.nih.gov/pubmed/27092494 http://dx.doi.org/10.3390/ijms17040454 |
work_keys_str_mv | AT kruszelnickaolga asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy AT swierszczjolanta asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy AT bednarekjacek asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy AT chyrchelbernadeta asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy AT surdackiandrzej asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy AT nesslerjadwiga asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy |